Spanish pharmaceutical company Grifols has entered into a partnership with Canadian Blood Services (CBS) to collect blood plasma from Canadian donors. Although CBS initially stated that all blood donations would be used for products within Canada, Grifols is now selling medicine made from Canadian-donated plasma abroad. This partnership aims to address immunoglobulin shortages and increase domestic production to meet the demand in Canada.
Grifols currently operates 17 plasma collection centers across Canada, acquired through the purchase of the country’s only other private plasma company. Additionally, the company acquired a manufacturing facility in Montreal to produce pharmaceutical products, with plans to expand its product offerings internationally. While the Montreal facility currently produces albumin, a product used to treat low blood volume, there are future plans to also manufacture immunoglobulins in Canada.
The process of fractionation, which separates plasma into its component proteins for specific uses, plays a crucial role in the production of plasma-derived products. Plasma collected in Canada is sent to Grifols’ manufacturing plant in the United States to produce immunoglobulin, with byproducts then used in the Montreal facility to produce albumin. CBS stated that these byproducts would otherwise be discarded, highlighting the efficiency of utilizing them to create products that benefit patients in other countries.
As a result of the partnership with Grifols, CBS has increased the domestic supply of immunoglobulin to 27% of demand from 15%. This boost in supply is attributed to both Grifols’ contribution and CBS’s efforts, including the operation of 11 plasma collection centers. Grifols, a long-time supplier of plasma-derived products, has played a significant role in supporting CBS in meeting the demand for plasma therapies in Canada.
The significant financial investment in plasma protein and related products underscores the importance of these therapies for CBS, constituting about 60% of its annual expenses. The majority of CBS’s revenue comes from provincial and territorial governments, highlighting the reliance on government funding to sustain its operations. Despite the ban on paying for blood donations in several provinces, Grifols has been allowed to operate in Ontario due to its association with CBS.
The partnership between Grifols and CBS has sparked controversy, with concerns raised about the use of Canadian-donated plasma for products sold internationally. Opposition to paid plasma collection in certain provinces reflects the ongoing debate surrounding the commercialization of blood donations and its impact on public trust in the healthcare system. Monitoring of operations by provincial health authorities is crucial to ensure that the needs of Canadian patients are prioritized in the production and distribution of plasma-derived products.
Key Takeaways:
– The partnership between Grifols and Canadian Blood Services has increased the domestic supply of plasma products in Canada, addressing immunoglobulin shortages.
– Plasma therapies constitute a significant portion of CBS’s annual expenses, highlighting the financial impact of these treatments on the organization.
– The controversy surrounding the use of Canadian-donated plasma for international sales raises questions about the commercialization of blood donations and its implications for the healthcare system.
– Ongoing monitoring of operations by provincial health authorities is essential to uphold public trust and prioritize the needs of Canadian patients in the production and distribution of plasma products.
Read more on theglobeandmail.com